Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Gilead Sciences: A Preview of Important HIV Drug Study Results

Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

Published
23 September 2014
From
The Street
Guidelines Advise Against Tenofovir for HIV Patients With Kidney Disease

HIV-positive patients who have reduced kidney function should take antiretroviral therapy, but should avoid regimens that contain tenofovir (Viread), according to updated treatment guidelines from the HIV Medicine Association (HIVMA).

Published
22 September 2014
From
The Body Pro
Stigma, ambivalence and other priorities – explaining poor adherence to PrEP and vaginal microbicides

HIV stigma, the danger of being mistakenly labelled as having HIV, ambivalence about the research process, confusion about the use of antiretrovirals to prevent infection, as well

Published
19 September 2014
By
Roger Pebody
PREZCOBIX™ now available for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.

Published
18 September 2014
From
Newswire.ca
CDC Launches HIV Treatment Awareness Campaign

“HIV Treatment Works” is a new awareness campaign from the U.S. Centers for Disease Control and Prevention (CDC).

Published
17 September 2014
From
Poz
First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

Cobicistat-boosted darunavir plus tenofovir alafenamide (TAF) and emtricitabine (FTC) yielded less bone and renal toxicity than darunavir/cobicistat plus tenofovir/emtricitabine (TDF/FTC) in randomized a phase 2 trial.

Published
16 September 2014
From
NATAP
Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla [1]. All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.

Published
16 September 2014
From
NATAP
Drug use strongly associated with sex, condomless sex and STIs in gay men living with HIV in England

A large survey of gay and bisexual men living with HIV and attending eight sexual health clinics in England has found that half of them had used

Published
16 September 2014
By
Gus Cairns
Sharon Lewin appointed to lead Doherty Institute for Infection and Immunity

Leading infectious disease expert Professor Sharon Lewin has been appointed the inaugural Director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne.

Published
15 September 2014
From
Peter Doherty Institute
Long acting HIV drugs to be developed

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

Published
15 September 2014
From
University of Liverpool press release

Filter by country